Women At The Top In Biopharma: The Odds And How To Beat Them
Biopharma companies in North America may be equal opportunity employers, but they are not equal opportunity promoters. Relative to their representation at the "grunt" level, far too few women make it on to the senior management teams, according to a survey of 316 US and Canadian publicly held pharma and biotech firms conducted by the Pharma Data Unit at Informa, IN VIVO's parent company.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.